Louise E Lansbury1, Sherie Smith2, Walter Beyer3, Emina Karamehic4, Eva Pasic-Juhas4, Hana Sikira4, Ana Mateus5, Hitoshi Oshitani6, Hongxin Zhao7, Charles R Beck8, Jonathan S Nguyen-Van-Tam9. 1. University of Nottingham, Nottingham, UK. Electronic address: Louise.Lansbury@nottingham.ac.uk. 2. University of Nottingham, Nottingham, UK. 3. Erasmus Medical Centre, Rotterdam, Netherlands. 4. University of Sarajevo, Sarajevo, Bosnia and Herzegovina. 5. Royal Veterinary College, London, UK. 6. Tohoku University, Japan. 7. National Infection Service, Public Health England, London, UK. 8. Field Epidemiology Service, Public Health England, UK; University of Bristol, Bristol, UK. 9. University of Nottingham, Nottingham, UK; Field Epidemiology Service, Public Health England, UK.
Abstract
BACKGROUND: The clinical effectiveness of monovalent influenza A(H1N1)pdm09 vaccines has not been comprehensively summarised. We undertook a systematic review and meta-analysis to assess vaccine effectiveness (VE) for adjuvanted and unadjuvanted vaccines. METHODS: We searched healthcare databases and grey literature from 11 June 2009 to 12 November 2014. Two researchers independently assessed titles and abstracts to identify studies for full review. Random effects meta-analyses estimated the pooled effect size of vaccination compared to placebo or no vaccination for crude and adjusted odds ratios (OR) to prevent laboratory confirmed influenza illness (LCI) and related hospitalization. VE was calculated as (1-pooled OR)∗100. Narrative synthesis was undertaken where meta-analysis was not possible. RESULTS: We identified 9229 studies of which 38 at moderate risk of bias met protocol eligibility criteria; 23 were suitable for meta-analysis. Pooled adjusted VE against LCI with adjuvanted and unadjuvanted vaccines both reached statistical significance (adjuvanted: VE=80%; 95% confidence interval [CI] 59-90%; unadjuvanted: VE=66%; 95% CI 47-78%); in planned secondary analyses, VE in adults often failed to reach statistical significance and pooled point estimates were lower than observed in children. Overall pooled adjusted VE against hospitalization was 61% (95% CI 14-82%); in planned secondary analyses, adjusted VE attained statistical significance in adults aged 18-64years and children for adjuvanted vaccines. Adjuvanted vaccines were significantly more effective in children compared to adults for both outcomes. CONCLUSIONS: Adjuvanted and unadjuvanted monovalent influenza A(H1N1)pdm09 vaccines were both effective in preventing LCI. Overall, the vaccines were also effective against influenza-related hospitalization. For both outcomes adjuvanted vaccines were more effective in children than in adults.
BACKGROUND: The clinical effectiveness of monovalent influenza A(H1N1)pdm09 vaccines has not been comprehensively summarised. We undertook a systematic review and meta-analysis to assess vaccine effectiveness (VE) for adjuvanted and unadjuvanted vaccines. METHODS: We searched healthcare databases and grey literature from 11 June 2009 to 12 November 2014. Two researchers independently assessed titles and abstracts to identify studies for full review. Random effects meta-analyses estimated the pooled effect size of vaccination compared to placebo or no vaccination for crude and adjusted odds ratios (OR) to prevent laboratory confirmed influenza illness (LCI) and related hospitalization. VE was calculated as (1-pooled OR)∗100. Narrative synthesis was undertaken where meta-analysis was not possible. RESULTS: We identified 9229 studies of which 38 at moderate risk of bias met protocol eligibility criteria; 23 were suitable for meta-analysis. Pooled adjusted VE against LCI with adjuvanted and unadjuvanted vaccines both reached statistical significance (adjuvanted: VE=80%; 95% confidence interval [CI] 59-90%; unadjuvanted: VE=66%; 95% CI 47-78%); in planned secondary analyses, VE in adults often failed to reach statistical significance and pooled point estimates were lower than observed in children. Overall pooled adjusted VE against hospitalization was 61% (95% CI 14-82%); in planned secondary analyses, adjusted VE attained statistical significance in adults aged 18-64years and children for adjuvanted vaccines. Adjuvanted vaccines were significantly more effective in children compared to adults for both outcomes. CONCLUSIONS: Adjuvanted and unadjuvanted monovalent influenza A(H1N1)pdm09 vaccines were both effective in preventing LCI. Overall, the vaccines were also effective against influenza-related hospitalization. For both outcomes adjuvanted vaccines were more effective in children than in adults.
Authors: Sonia Jain; Parakkal Jovvian George; Wanyan Deng; Joseph Koussa; Kaela Parkhouse; Scott E Hensley; Jiu Jiang; Jie Lu; Zhuyun Liu; Junfei Wei; Bin Zhan; Maria Elena Bottazzi; Hao Shen; Sara Lustigman Journal: Vaccine Date: 2018-06-14 Impact factor: 3.641
Authors: Ann M Arvin; Katja Fink; Michael A Schmid; Andrea Cathcart; Roberto Spreafico; Colin Havenar-Daughton; Antonio Lanzavecchia; Davide Corti; Herbert W Virgin Journal: Nature Date: 2020-07-13 Impact factor: 49.962
Authors: Daniel A Salmon; Paul Henri Lambert; Hanna M Nohynek; Julianne Gee; Umesh D Parashar; Jacqueline E Tate; Annelies Wilder-Smith; Kenneth Y Hartigan-Go; Peter G Smith; Patrick Louis F Zuber Journal: BMJ Glob Health Date: 2021-05
Authors: Amanda L Wilkins; Dmitri Kazmin; Giorgio Napolitani; Elizabeth A Clutterbuck; Bali Pulendran; Claire-Anne Siegrist; Andrew J Pollard Journal: Front Immunol Date: 2017-12-13 Impact factor: 7.561
Authors: Lauren C Ramsay; Sarah A Buchan; Robert G Stirling; Benjamin J Cowling; Shuo Feng; Jeffrey C Kwong; Bryna F Warshawsky Journal: BMC Med Date: 2017-08-21 Impact factor: 8.775